Skip to search formSkip to main contentSkip to account menu

monoclonal antibody 2021

Known as: concizumab, mAb 2021 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the… 
2019
2019
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial
Background Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the… 
2017
2017
Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A
Introduction: Concizumab is a humanized monoclonal antibody (mAb) that enhances thrombin generation (TG) potential by inhibiting… 
2017
2017
A promising new treatment horizon for haemophilia A.
2014
2014
thrombin generation is restored in transient haemophilic rabbits after administration of concizumab, a monoclonal, tissue factor pathway inhibitor antibody
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)